Think Twice Before Investing in Faster Reg Process for Novel Devices, warns AusBiotech
This article was originally published in Clinica
Executive Summary
Australia's biotech industry association, AusBiotech, has cautioned the government against investing resources in creating a new accelerated pathway for the approval of novel medical devices as this would amount to diverting resources away from making "more desirable" changes to the existing approval pathways.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.